LuciCer — Ceritinib 150 mg, 50 pcs, Lucius

LuciCer — Ceritinib Capsules 150 mg, 50 Capsules

Product code: 517

29055₴ 31692₴ -8% On order · from 10 days

Analogues

Cerixen LuciCer
1
Active ingredient
Dosage
150 mg
Dosage form Capsules
Capsules per pack 50

LuciCer is an advanced targeted antineoplastic agent belonging to the tyrosine kinase inhibitor class, indicated for the treatment of non-small cell lung cancer. The active pharmaceutical ingredient is ceritinib at a strength of 150 mg supplied as hard gelatin capsules (Ceritinib Capsules 150 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Ceritinib is an oral, selective, potent anaplastic lymphoma kinase (ALK) inhibitor. It effectively blocks ALK phosphorylation and downstream signaling pathways leading to tumor cell proliferation and induction of apoptosis. The drug is highly effective both in patients who have not previously received ALK inhibitors (such as crizotinib) and upon disease progression following prior therapy, while also demonstrating blood-brain barrier penetration.

Supplied in a package containing 50 capsules of 150 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciCer 150 mg:

  • ✅ Next-Generation Potent ALK Inhibitor: High selectivity for ALK kinase to suppress tumor growth.
  • ✅ Overcoming Resistance: Efficacy in crizotinib-intolerant or resistant tumors.
  • ✅ CNS Metastasis Control: Ability to penetrate the blood-brain barrier.
  • ✅ Convenient Oral Dosing: Taken orally once daily.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Zykadia).

LuciCer is supplied as hard gelatin capsules for oral administration.

Qualitative and Quantitative Composition per Capsule:

  • Active Ingredient: Ceritinib — 150 mg.
  • Excipients: Microcrystalline cellulose, hydroxypropyl cellulose, crospovidone, magnesium stearate, colloidal anhydrous silica. Capsule shell: gelatin, titanium dioxide, indigotine.

Packaging and Presentation: Hard capsules, 150 mg strength. Each package contains 50 capsules along with prescribing information. Labeled with LuciCer (Ceritinib Capsules 150 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Ceritinib is an oral, highly selective ALK tyrosine kinase inhibitor. ALK receptor tyrosine kinases are frequently involved in oncogenic translocations in non-small cell lung cancer. Ceritinib inhibits ALK autophosphorylation, blocks proliferative signaling, and induces cancer cell apoptosis. Active against crizotinib resistance mutations (e.g., L1196M).

Pharmacokinetics:

  • Absorption: Following oral administration, ceritinib absorption is relatively slow; peak plasma concentration (Tmax) is achieved within approximately 4 to 6 hours. High-fat meals significantly increase drug bioavailability.
  • Distribution: Human plasma protein binding is approximately 97%.
  • Metabolism: Extensively metabolized in the liver, primarily via cytochrome P450 enzymes (mainly CYP3A4).
  • Elimination: Excreted predominantly via feces (approx. 92%) and renally (approx. 1.3%). Terminal elimination half-life (T1/2) averages approximately 41 hours.

LuciCer is indicated in adult patients for:

  • ALK-Positive Non-Small Cell Lung Cancer (NSCLC): Treatment of adult patients with advanced ALK-positive non-small cell lung cancer previously treated or untreated with ALK inhibitors (including crizotinib).

LuciCer is administered orally once daily every day at approximately the same time.

Dosing Regimen:
The recommended standard dose is 450 mg (three 150 mg capsules) once daily with food. Continue treatment until disease progression or unacceptable toxicity occurs.

Administration Guidelines:
Capsules should be taken with food (a regular or light meal) with water. Taking it with food improves gastrointestinal tolerability. Capsules must be swallowed whole; do not break, crush, or open. If a dose is missed, take it as soon as possible unless the next dose is due within 12 hours.

Administration of LuciCer is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to ceritinib or any excipient.
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic Impairment: Pronounced liver dysfunction.

Ceritinib is metabolized primarily via CYP3A4:

  • Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, grapefruit juice): Significantly elevate ceritinib plasma concentrations and toxicity risks (avoid concurrent use).
  • Strong CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Decrease ceritinib blood concentrations and reduce efficacy (avoid concurrent use).
  • QT-Prolonging Drugs: Co-administration requires regular ECG and electrolyte monitoring.

Pregnancy:
LuciCer is contraindicated during pregnancy. Based on its mechanism of action, ceritinib may cause fetal harm and embryotoxicity. Females of reproductive potential and male partners must utilize effective reliable contraception during treatment and for at least 3 months following the final dose.

Lactation:
Excretion of ceritinib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Gastrointestinal Tract: Diarrhea, nausea, vomiting, abdominal pain, decreased appetite, constipation (prompt supportive therapy required).
  • Hepatic Abnormalities: Elevations in liver transaminases (ALT, AST) and bilirubin levels (routine laboratory monitoring required).
  • General Disorders: Fatigue, asthenia, rash, pruritus.
  • Cardiovascular System: QT interval prolongation on ECG, bradycardia.
  • Laboratory Abnormalities: Increased blood creatine phosphokinase (CPK), hyperglycemia.

Symptoms:
Specific acute overdose symptoms of ceritinib are unestablished. Anticipated manifestations include exacerbated adverse reactions (gastrointestinal and hepatotoxicity).

Treatment:
No specific antidote exists. In case of overdose, withhold treatment and initiate supportive and symptomatic care under medical observation.

Storage Requirements for LuciCer 150 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciCer 150 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Ceritinib Capsules 150 mg, and 50 Capsules count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 17.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00